NASDAQ: CDMOAvid Bioservices Inc Stock
$10.48-0.15 (-1.41%)
Updated Oct 7, 2024
CDMO Price
$10.48
Fair Value Price
N/A
Market Cap
$668.57M
52 Week Low
$4.07
52 Week High
$12.48
P/E
-4.6x
P/B
11.4x
P/S
4.67x
PEG
N/A
Dividend Yield
N/A
Revenue
$142.36M
Earnings
-$144.17M
Gross Margin
6.3%
Operating Margin
-16.69%
Profit Margin
-101.3%
Debt to Equity
4.71
Operating Cash Flow
$8M
Beta
1.28
Next Earnings
Dec 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CDMO Overview
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CDMO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CDMO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CDMO is poor value based on its book value relative to its share price (11.4x), compared to the US Biotechnology industry average (5.95x)
P/B vs Industry Valuation
CDMO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CDMO due diligence checks available for Premium users.
Be the first to know about important CDMO news, forecast changes, insider trades & much more!
CDMO News
Valuation
CDMO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.6x
Industry
-111.33x
Market
26.63x
CDMO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.4x
Industry
5.95x
CDMO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CDMO's financial health
Profit margin
Revenue
$40.2M
Net Income
-$5.5M
Profit Margin
-13.8%
CDMO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CDMO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$334.6M
Liabilities
$276.0M
Debt to equity
4.71
CDMO's short-term assets ($103.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CDMO's long-term liabilities ($204.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CDMO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CDMO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.7M
Investing
-$1.3M
Financing
$266.0k
CDMO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CDMO vs Biotech Stocks
Avid Bioservices Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.